Duseja A, Das A, Krishan DR, Kumar CY, Thumburu KK, Bhadada S, Bhansali A

Language: English
References: 25
Page: 222-226
PDF size: 127.12 Kb.

Text Extraction

Background: Insulin resistance plays an important role in the pathogenesis of NAFLD. Pharmacological treatment of patients with NAFLD is still evolving. Insulin sensitizing drugs like metformin may be effective in these patients. Twenty five adult patients with NAFLD who did not achieve normalization of alanine transaminases (ALT) after 6 months of lifestyle interventions and UDCA were treated with metformin 500mg tid for 6 months. Insulin resistance was determined by HOMA- IR. Liver function tests were done monthly and patients were defined having no response, partial response or complete biochemical response depending on the change in ALT. Results were compared with 25 patients with NAFLD from the same cohort treated only with lifestyle interventions (disease controls). Results: Thirteen (52%) patients had class III (n = 5) or class IV (n = 8) disease amounting to histological NASH. Of these 13 patients none had severe inflammation and none had stage 4 fibrosis (cirrhosis). All 25 patients with NAFLD had insulin resistance in comparison to healthy controls. In comparison to disease controls (127.5 ± 41.8 vs. 118 ± 21.6 p = NS), all patients treated with metformin had partial biochemical response (mean ALT 122.2 ± 26.8 vs 74.3 ± 4.2 p ‹ 0.01) and 14 (56%) of them achieved complete normalization of ALT. Conclusions: Metformin is effective to achieve biochemical response in patients with NAFLD who do not respond to lifestyle interventions and UDCA.

REFERENCES

1. Falck–Ytter Y, Younossi ZM, Marchesini G, Mc Cullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.

2. Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y. Prevalence of obesity, diabetes mellitus and hyperlipidemia in patients with cryptogenic liver cirrhosis. Trop Gastroenterol 2004; 25: 15-17.

3. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.

4. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Sanchez-Avila F, Montano-Reyes MA, Uribe M. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. World J Gastroenterol 2006 28; 12: 7826-31.

5. Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, Chawla Y. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis – a preliminary report. Indian J Gastroenterol 2004; 23: 12-5.

6. Marchesini G, Brizi M, Bianchi G, Tomasserti S, Zoli M, Melchionda N. Metformin in nonalcoholic steatohepatitis. Lancet 2001; 358: 893-4.

7. Uygun A, Kadayifci A, Isik AT, Ozqurtas T, Deveci S, Tuzun A, Yesilova Z, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-44.

8. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.

9. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-90.

10. Steering Committee of the Western Pacific region of the World Health Organization. The International Association for the study of Obesity and the International Study Task Force. The Asia-Pacific perspective; redefining obesity and its treatment, 8-56. Australia: Health Communications; 2000.

11. Dhiman RK, Duseja A, Chawla Y. Asians need different criteria for defining overweight and obesity. Arch Intern Med 2005; 165: 1069-1070.

12. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications – Part 1: Diagnosis and classification of diabetes mellitus, 31-3. Geneva: World Health Organisation; 1999.

13. Expert panel on detection evaluation and treatment of high cholesterol in adults. Executive summary of the third report of the national Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment panel III). JAMA 2001; 285: 2486-97.

14. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 16: 1413-19.

15. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander – Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.

16. Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. Clinicopathological profile of Indian patients with nonalcoholic fatty liver disease is different from that in the west. Dig Dis Sci 2007; 52: 2368-74.

17. Duseja A, Das A, Dhiman RK, Chawla YK, Das R, Bhadada S, Sialy R, et al. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. World J Gastroenterol 2007; 13: 649-50.

18. Day C, James O: Steatohepatitis: a tale of two «hits»? (Editorial). Gastroenterology 1998; 114: 842-5.

19. Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 148-55.

20. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic induced steatohepatitis: A pilot study. Hepatology 1996; 23: 1464-67.

21. Lindor KD, Kowdley KV, Heathcote EJ, Harrisson ME, Jorgensen R, Angulo P, Lymp JF, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.

22. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, Troglitazone in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.

23. Neuschwander–Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR - g Ligand rosiglitazone. Hepatology 2003; 38: 1008-17.

24. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.

25. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med 2000; 6: 998-1003.